Aiming to turn £10k into £20k? Here are 3 FTSE 250 shares for investors to consider

Our writer demonstrates how three vastly different FTSE 250 stocks could all double an investment over a decade – and then some.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Mixed-race female couple enjoying themselves on a walk

Image source: Getty Images

The FTSE 250 doesn’t get as much attention as its older sibling, the FTSE 100 — but maybe it should. Over the past two decades, the mid-cap index has comfortably outperformed the UK’s blue-chip benchmark. It’s a diverse mix of companies that are typically further along than early-stage growth stocks, but still small enough to offer exciting growth potential.

Naturally, investing in mid-cap stocks comes with extra risk, as they can be more sensitive to economic headwinds than global giants. But for long-term investors willing to do the research, the index offers plenty of compelling opportunities.

Some shares could even turn a £10,000 investment into £20,000 — or more — over the next 10 years.

Here are three that I think are worth considering.

Primary Health Properties 

Primary Health Properties (LSE: PHP) is a real estate investment trust (REIT) focused on modern, purpose-built healthcare facilities – many of which are leased long term to NHS tenants. That makes its income about as reliable as it gets in the REIT space.

Please note that tax treatment depends on the individual circumstances of each client and may be subject to change in future. The content in this article is provided for information purposes only. It is not intended to be, neither does it constitute, any form of tax advice.

The dividend yield currently sits around 7%, and with compounding via reinvestment, a £10,000 investment could grow to roughly £22,000 over a decade. What’s more, dividends have grown consistently at an average of 3.5% annually, providing a nice cushion against inflation.

There are a few red flags, though. The shares look expensive with a price-to-earnings (P/E) ratio of 30, and the dividend payout ratio is worryingly high. If earnings falter, the dividend could be vulnerable. Still, its defensive sector and government-backed income streams are hard to ignore.

Spectris

Spectris (LSE: SXS) makes precision instrumentation and controls used in high-tech industrial settings. It’s a name that doesn’t often trend. But quietly, this FTSE 250 firm has been making long-term shareholders very happy. Over the past three decades, Spectris has delivered triple-digit gains each decade — and then some.

Despite its strong track record, it still trades at a price-to-earnings growth (PEG) ratio of just 0.26, suggesting it could be undervalued relative to its growth prospects. Operating margins are high, and return on equity sits close to 18%.

The dividend yield is modest, but payments have grown for 19 straight years and remain well covered by earnings. Risks include a slowdown in industrial demand or underperformance in key end markets. But for a steady growth stock with a quality track record, it’s one I’d keep an eye on.

OSB Group

OSB Group (LSE: OSB) is one of the UK’s best-kept secrets in financial services, combining growth with generous dividends. Over the past decade, the share price has climbed 90% and it currently yields 6%. If the same growth and yield held for the next 10 years (which isn’t guaranteed), it could turn £10k into £28,200.

However, the business is heavily exposed to the specialist mortgage market. If house prices tumble or bad debts spike, profits could take a hit. Its debt load is already quite high – almost double its equity – so a dip in profit could shift priorities away from dividends.

Importantly, the payout ratio is a manageable 43%, giving it plenty of headroom. That valuation also looks compelling: a P/E ratio of just 7.4 and a price-to-book (P/B) ratio below 1.

Mark Hartley has positions in OSB Group and Primary Health Properties Plc. The Motley Fool UK has recommended Primary Health Properties Plc and Spectris Plc. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Growth Shares

Artillery rocket system aimed to the sky and soldiers at sunset.
Investing Articles

Up 325% in 5 years! But are BAE System shares still a no-brainer buy?

BAE Systems shares would have been a brilliant buy five years ago. But could they still offer excellent returns if…

Read more »

Close-up as a woman counts out modern British banknotes.
Investing Articles

£10,000 invested in BAE shares at the beginning of 2026 is now worth…

Paul Summers tips his hat to those who invested in BAE Systems shares when markets opened back up in January.…

Read more »

Investing Articles

Just check out the latest bumper forecasts for Lloyds, NatWest and Barclays shares

Harvey Jones says Barclays shares have had a terrific year and there could be more action to come. So what's…

Read more »

Senior Adult Black Female Tourist Admiring London
Investing Articles

Meet the skyrocketing FTSE 250 stocks up by more than 300% in five years!

These FTSE 250 stocks have delivered market-thrashing returns for shareholders in recent years. But are any still worth considering today?

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

£20,000 invested in BP shares 1 year ago is now worth…

BP shares have rocketed in the past 12 months, yet analysts think the real growth story is only just beginning,…

Read more »

GSK scientist holding lab syringe
Investing Articles

GSK’s share price is under £22, but with a ‘fair value’ much higher, is it time for me to buy more right now? 

GSK’s share price rose over the last year, but a huge gap remains between its price and fair value —…

Read more »

UK supporters with flag
Investing Articles

Is Wise now the UK stock market’s top growth share?

Wise rose around 4% in the UK stock market yesterday, bringing its four-year gain to 135%. Why are investors warming…

Read more »

Warhammer World gathering
Investing Articles

£20,000 invested in this FTSE 100 stock 10 years ago is now worth this astonishing amount…

This FTSE 100 stock's delivered an amazing return over the past 10 years. James Beard considers whether it’s worth holding…

Read more »